| Inflammatory Bowel Disease |
1 |
1 |
| Remission |
0 |
0.85 |
| Biologic Therapy |
0 |
0.76 |
| Anti-Tumor Necrosis Factor (Anti-TNF) |
0 |
0.99 |
| Crohn Disease |
0 |
0.44 |
| Ulcerative Colitis |
0 |
0.43 |
| Colitis |
0 |
0.26 |
| Tumor |
0 |
0.2 |
| Tumor Necrosis Factor-Alpha |
0 |
0.18 |
| Endoscopy |
0 |
0.9 |
| Quality of Life |
0 |
0.13 |
| Revenue and Practice Management |
0 |
0.13 |
| Shared Decision-Making |
0 |
0.13 |
| Health Insurance |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Patient Safety |
0 |
0.09 |
| Pregnancy |
0 |
0.09 |
| Adverse Effects |
0 |
0.07 |
| Anti-inflammatory Agents |
0 |
0.07 |
| C-Reactive Protein (CRP) |
0 |
0.07 |
| Continuing Medical Education |
0 |
0.07 |
| Corticosteroids |
0 |
0.07 |
| Immunomodulator |
0 |
0.07 |
| Insurance |
0 |
0.07 |
| Medical Innovations |
0 |
0.07 |
| Surgery |
0 |
0.07 |